These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38071314)

  • 41. Influence of adjuvants in inducing immune responses to different epitopes included in a multiepitope, multivalent, multistage Plasmodium falciparum candidate vaccine (FALVAC-1) in outbred mice.
    Rafi-Janajreh A; Tongren JE; Kensil C; Hackett C; Candal F; Lal A; Udhayakumar V
    Exp Parasitol; 2002 May; 101(1):3-12. PubMed ID: 12243733
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.
    Li Y; Leneghan DB; Miura K; Nikolaeva D; Brian IJ; Dicks MD; Fyfe AJ; Zakutansky SE; de Cassan S; Long CA; Draper SJ; Hill AV; Hill F; Biswas S
    Sci Rep; 2016 Jan; 6():18848. PubMed ID: 26743316
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A dual-antigen malaria vaccine targeting Pb22 and Pbg37 was able to induce robust transmission-blocking activity.
    Gao W; Qiu Y; Zhu L; Yu X; Yang F; Chen M; He G; Liu Y; Cui L; Liu F; Zhu X; Cao Y
    Parasit Vectors; 2023 Dec; 16(1):455. PubMed ID: 38098083
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A.
    Brando C; Ware LA; Freyberger H; Kathcart A; Barbosa A; Cayphas S; Demoitie MA; Mettens P; Heppner DG; Lanar DE
    Infect Immun; 2007 Feb; 75(2):838-45. PubMed ID: 17101665
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex.
    Przysiecki C; Lucas B; Mitchell R; Carapau D; Wen Z; Xu H; Wang XM; Nahas D; Wu C; Hepler R; Ottinger E; Ter Meulen J; Kaslow D; Shiver J; Nardin E
    Front Cell Infect Microbiol; 2012; 2():146. PubMed ID: 23226683
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.
    Tougan T; Aoshi T; Coban C; Katakai Y; Kai C; Yasutomi Y; Ishii KJ; Horii T
    Hum Vaccin Immunother; 2013 Feb; 9(2):283-90. PubMed ID: 23291928
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum.
    Kapulu MC; Da DF; Miura K; Li Y; Blagborough AM; Churcher TS; Nikolaeva D; Williams AR; Goodman AL; Sangare I; Turner AV; Cottingham MG; Nicosia A; Straschil U; Tsuboi T; Gilbert SC; Long CA; Sinden RE; Draper SJ; Hill AV; Cohuet A; Biswas S
    Sci Rep; 2015 Jun; 5():11193. PubMed ID: 26063320
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination.
    Parzych EM; Miura K; Long CA; Burns JM
    PLoS One; 2020; 15(4):e0232355. PubMed ID: 32348377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
    Draper SJ; Biswas S; Spencer AJ; Remarque EJ; Capone S; Naddeo M; Dicks MD; Faber BW; de Cassan SC; Folgori A; Nicosia A; Gilbert SC; Hill AV
    J Immunol; 2010 Dec; 185(12):7583-95. PubMed ID: 21098232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant
    Parzych EM; Miura K; Ramanathan A; Long CA; Burns JM
    Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993460
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity of full-length P. vivax rPvs48/45 protein formulations in BALB/c mice.
    Arévalo-Herrera M; Miura K; Solano E; Sebastián Ramírez J; Long CA; Corradin G; Herrera S
    Vaccine; 2022 Jan; 40(1):133-140. PubMed ID: 34802791
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional Characterization and Comparison of
    Nikolaeva D; Illingworth JJ; Miura K; Alanine DGW; Brian IJ; Li Y; Fyfe AJ; Da DF; Cohuet A; Long CA; Draper SJ; Biswas S
    Mol Cell Proteomics; 2020 Jan; 19(1):155-166. PubMed ID: 29089373
    [No Abstract]   [Full Text] [Related]  

  • 53. A nanoparticle vaccine displaying the ookinete PSOP25 antigen elicits transmission-blocking antibody response against Plasmodium berghei.
    Yao G; Min H; Yu X; Liu F; Cui L; Cao Y
    Parasit Vectors; 2023 Nov; 16(1):403. PubMed ID: 37932796
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel asexual blood-stage malaria vaccine candidate: PfRipr5 formulated with human-use adjuvants induces potent growth inhibitory antibodies.
    Takashima E; Nagaoka H; Correia R; Alves PM; Roldão A; Christensen D; Guderian JA; Fukushima A; Viebig NK; Depraetere H; Tsuboi T
    Front Immunol; 2022; 13():1002430. PubMed ID: 36389677
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inclusion of an Optimized
    Eacret JS; Parzych EM; Gonzales DM; Burns JM
    J Immunol; 2021 Apr; 206(8):1817-1831. PubMed ID: 33789984
    [No Abstract]   [Full Text] [Related]  

  • 56. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas.
    Baptista BO; de Souza ABL; Riccio EKP; Bianco-Junior C; Totino PRR; Martins da Silva JH; Theisen M; Singh SK; Amoah LE; Ribeiro-Alves M; Souza RM; Lima-Junior JC; Daniel-Ribeiro CT; Pratt-Riccio LR
    Malar J; 2022 Jan; 21(1):6. PubMed ID: 34983540
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduced immunogenicity of Plasmodium falciparum gamete surface antigen (Pfs48/45) in mice after disruption of disulphide bonds - evaluating effect of interferon-γ-inducible lysosomal thiol reductase.
    Merino KM; Bansal GP; Kumar N
    Immunology; 2016 Aug; 148(4):433-47. PubMed ID: 27177843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 59. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
    PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.
    Lynch MM; Cernetich-Ott A; Weidanz WP; Burns JM
    Clin Vaccine Immunol; 2009 Mar; 16(3):293-302. PubMed ID: 19116303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.